Rachel Tsunemoto Hislop brings an unusually complete perspective to life science investing, having worked as a stem-cell and developmental neurobiology researcher at UC San Diego, then in medical affairs at Acorda Therapeutics before moving into venture capital—giving her visibility across the entire pipeline from basic research through commercialization that most investors lack. As Director of Research at Two Bear Capital, she leads a San Diego-based research team that produces data-driven insights to support investment decisions, a more formal research function than most early-stage funds maintain.